53 e mails da pfizer
You're referring to the 53 emails from Pfizer that were released as part of a Freedom of Information Act (FOIA) request. These emails were sent between 2012 and 2015 and relate to the company's efforts to influence the scientific debate around the safety and efficacy of its products, including its COVID-19 vaccine.
The emails were obtained by the non-profit organization, Public Citizen, and were released in 2021. They show that Pfizer employees and contractors were actively working to shape the narrative around the company's products, including by:
- Influencing scientific research and publications: Pfizer employees and contractors were involved in drafting and editing scientific papers, as well as providing feedback on research proposals and manuscripts.
- Shaping public opinion: Pfizer employees and contractors were involved in creating and disseminating messaging and talking points to the media, policymakers, and the public.
- Lobbying government officials: Pfizer employees and contractors were involved in lobbying government officials, including FDA regulators, to influence policy decisions and ensure favorable outcomes for the company.
- Coordinating with other industry players: Pfizer employees and contractors were involved in coordinating with other pharmaceutical companies, industry associations, and advocacy groups to advance the company's interests.
Some of the specific examples of emails that were released include:
- An email from a Pfizer employee to a FDA regulator, expressing concerns about a proposed study on the safety of Pfizer's cholesterol-lowering drug, Lipitor.
- An email from a Pfizer contractor to a journalist, providing talking points and background information on the company's COVID-19 vaccine.
- An email from a Pfizer employee to a government official, urging the official to support the company's efforts to expand the use of its antibiotic, Zithromax.
The release of these emails has raised concerns about the influence of pharmaceutical companies on the scientific and regulatory process, and has sparked calls for greater transparency and accountability in the industry.